| Abstrakt: |
A comprehensive review conducted in Quetta, Pakistan explores the potential of TAU protein antibodies as therapies for Alzheimer's disease (AD). The study investigates the safety and efficacy of these antibodies through a thorough analysis of clinical trials and academic publications. The research suggests that TAU protein antibodies show promise in treating AD, with some improvement in cognitive deterioration. However, caution is advised due to safety concerns, particularly regarding imaging abnormalities caused by amyloid. Further studies are needed to optimize efficacy, safety, and cost-effectiveness. [Extracted from the article] |
